Abstract: Disclosed are compositions and methods effective for inhibiting restenosis. In particular, the present invention provides compositions for inhibiting undesired smooth muscle cell growth or proliferation following angioplasty in mammals, said composition comprising active agents comprising a very water-soluble derivative of cyclodextrin. The invention also provides methods of inhibiting undesired smooth muscle cell growth or proliferation following angioplasty in mammals comprising orally administering to the mammal a growth-inhibiting amount of an active agent comprising a very water-soluble derivative of cyclodextrin.

Abstract: The crystalline mixture solid containing maltitol of the present invention has a crushed and relatively tight crystal structure which can be observed at 1,000 magnifications by a scanning electron microscope, an apparent specific gravity in the range of 0.650-0.750, an oil absorptivity of the powdered crystalline mixture solid containing maltitol having a particle size from 50 mesh to 20 mesh in the range of 7.0%-17%, in other words, is relatively heavy in apparent specific gravity and low in oil absorptivity, and the crystalline mixture solid containing maltitol is prepared by continuously supplying an aqueous solution of maltitol to an extruder provided with elongated cooling and kneading zones, cooling and kneading it in the presence of seed crystals to form a maltitol magma, and continuously extruded from a nozzle.

Abstract: Previously unrecognized polysaccharide products are extracted from either whole Lesquerella fendleri seed or commercially processed and oil-extracted seed meal or presscake or other seed material. Processes used include the steps of: (1) combining the seed material with an aqueous solution; (2) high speed stirring or sonification of the resultant seed material for the separation of the polysaccharide from the seed; and (3) isolation of the polysaccharide from the aqueous filtrate. The resultant polysaccharides are highly polymeric and enhance solution viscosities over a wide range of pH, bleaching and salt conditions.

Abstract: This invention involves new compositions and methods of use and delivery of amorphous strontium compounds such as: amorphous strontium phosphate (ASP), amorphous strontium phosphate fluoride (ASPF), amorphous strontium calcium phosphate (ASCP), amorphous strontium calcium carbonate phosphate (ASCCP), amorphous strontium carbonate phosphate fluoride (ASCPF) and amorphous strontium calcium carbonate phosphate fluoride (ASCCPF) for use in remineralizing and fluoridating teeth. These amorphous compounds or solutions which form the amorphous compounds, when applied either onto or into dental tissue prevent and/or repair dental weaknesses such as dental caries, exposed roots and dentin sensitivity.

Abstract: The use of IGF-II for preparing a medicament for the regeneration of muscle tissue; and methods for medical treatment for the purpose of regenerating muscle tissue, for minimizing scar formation during healing of a wound or for preventing undesired tissue adhesion after injury, such as after surgery.

Abstract: Polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are disclosed. Compositions and methods for separating a molecular species, including but not limited to a biologically active protein, from a mixture, for the storage of protein factors and for the therapeutic biodelivery of protein factors which employ the polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are also disclosed.

Abstract: Methods for reducing the risk of or preventing infections by bacterial pathogens in vivo. In particular, a method for reducing the risk of P. aeruginosa infection in vivo in compromised hosts such as cystic fibrosis patients. The methods involve the use of dextran or dextran sulphate as the active ingredient.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl; are provided.

Abstract: A pharmaceutical composition having a form suitable for transmucosal administration containing progesterone and/or 17-.beta.-estradiol as an active ingredient.

Abstract: Low pH acidic compositions for uses related generally to chemical, pharmaceutical and cosmetic agents and more particularly, but not limited to, used as bactericides, fungicides, germicides and virucides; all having pH values of less than about 2.0 in their final form. These low pH acidic compositions generally comprise two phases in solution. Phase I comprises from about 2 to about 98 weight percent of varying percentages of several chemical, pharmaceutical and cosmetic substances.Phase II comprises from about 2 to about 99 weight percent of an active aqueous acidic component having a pH value of less than about 1.

Abstract: The present invention relates to an agent for the suppression or lowering of blood lipids, cholesterol and neutral fats, which is derived from a plant and comprises, as an effective ingredient, an edible dietary fiber which contains cellulose and lignin as its main constituents and maintains the cellulose and lignin in a bonded state as in the plant.

Abstract: An exercise regimen which enhances exercise endurance and performance. The regimen includes pre-exercise hydration with a glycerol solution combined with hydration during exercise with a glycerol based solution to prolong hydration effects. The first pre-exercise glycerol solution regimen begins 2 hours prior to exercise and ends 1/2 hour before exercise begins. The hydration during exercise regimen combines glycerol with a carbohydrate and sodium to prolong fluid retention.

Abstract: The present invention relates to methods for the treatment of prevention of osteoporosis by the administration of a vitamin D glycoside or vitamin D orthoester glycoside, or an analog thereof.

Abstract: The invention concerns a complex of cyclodextrin and an organic biocide, wherein the organic biocide has a maximum water-solubility of 0.15% (w/v) at a temperature of 25.degree. C., a process for the production of the complex as well as the use of the complex for preserving aqueous solutions. In addition the invention concerns a diagnostic test solution which contains at least one complex according to the invention and a preserved diagnostic test kit which comprises test reagents and at least one complex according to the invention.

Abstract: Particulate flavor composition comprising a flavor oil fixed in a particulate low cariogenic matrix of hydrogenated starch hydrolysate and a maltodextrin having a dextrose equivalent value of less than 20.A process for the encapsulation of a flavor oil comprising forming a homogeneous mixture of the flavor oil with(a) from about 40 to about 85 percent by weight of a particulate polyol consisting of hydrogenated starch hydrolysate,(b) from about 10 to about 30 percent by weight of a maltodextrin having a dextrose equivalent of less than 20,(c) an emulsifier and water,and spray-drying the resultant mixture to form a particulate product of from about 0.15 to about 0.85 g/cc bulk free flow density.

Abstract: A process for preparing a sucrose fatty acid polyester comprising mixing a sucrose ether having an average degree of etherification of from about 4 to about 8 with a basic catalyst and an excess of a fatty acid lower alkyl ester, heating the resultant mixture to a temperature of from about 120.degree. C. to about 180.degree. C. at a pressure of up to about 10 mm of mercury while removing the alcohol formed during the formation of the sucrose fatty acid polyester, and then separating the sucrose fatty acid polyester from the reaction mixture. The sucrose fatty acid polyester is a synthetic low calorie fat substitute and is useful in preparing edible non-digestible food products.

Abstract: The use of a hydroxyethyl starch specification with a molecular weight M.sub.W of 110,000 to 150,000, a substitution level MS of 0.38 to 0.5, a substitution level DS of 0.32 to 0.45, and a C.sub.2 /C.sub.6 ratio from 8 to 20 for improvement of microcirculation in a peripheral arterial circulation disorder, in particular in already existing peripheral arterial occlusive disease in Stage II according to Fontaine. This hydroxyethyl starch specification can be used in suitable concentrations, e.g., as 6 wt.-% or 10 wt.-% solution, whereby these solutions optionally contain conventional adjuvants and additives.

Abstract: O-derivatized alginic acid antigens capable of eliciting opsonizing antibodies in vivo are described. The O-derivatized antigens show enhanced antigenicity and immunogenicity relative to native, non-O-derivatized alginic acid antigens, particularly the MEP antigen of P. aeruginosa. Pharmaceutical compositions containing the O-derivatized antigens of the invention are also described. The invention also pertains to use of the compositions as vaccines, in immunodiagnostic assays, and in methods for producing monoclonal antibodies reactive against the antigen.Methods for forming O-derivatized alginic acid antigens of the invention are described. A non-O-derivatized starting material is reacted in a solvent with an alkyl anhydride derived from a fatty acid.

Abstract: Coated pharmaceutical dosage forms which are resistant to gastric juice and release their active ingredient rapidly at a predetermined pH value in the range from pH 5 to pH 8 are obtained in accordance with the invention by coating pharmaceutical dosage forms with an aqueous dispersion containing dispersed latex particles of a first polymer which contains carboxyl groups and is water soluble between pH 5 and pH 8 and of a second water insoluble film forming polymer, in a weight ratio between 60:40 and 5:95.

Abstract: This invention relates to glucopyranose compounds of formula (I) and (IA) ##STR1## and the non-toxic salts thereof wherein the substituents are as defined herein. Such materials possess enhancing activity of cellular immunity (e.g. mitogenic activity) to living tissue and therefore are useful as anti-tumor agents.